Gracell Biotechnologies Announces Presentation of First-in-Human Data of GC012F a First-in-Class FasTCAR-enabled Dual-targeting BMCA/CD19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Multiple Myeloma at 2020 ASH Annual Meetin ...Middle East

SUZHOU and SHANGHAI, China, Dec. 5, 2020 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced an interim readout to...

Hence then, the article about gracell biotechnologies announces presentation of first in human data of gc012f a first in class fastcar enabled dual targeting bmca cd19 car t cell therapy for patients with relapsed or refractory multiple myeloma at 2020 ash annual meetin was published today ( Saturday 05/12/2020 - 11:46 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Gracell Biotechnologies Announces Presentation of First-in-Human Data of GC012F a First-in-Class FasTCAR-enabled Dual-targeting BMCA/CD19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Multiple Myeloma at 2020 ASH Annual Meetin )

Also on site :

• Celine Dion to Make Concert Comeback in Paris
• How Chuck Norris Created the Manosphere
• Hacks' Deborah Vance Fights To Reclaim The Spotlight In Final Season Trailer — Plus, Get Premiere Date